The links provided below are specially curated for healthcare professionals and research scientists in the UK, to offer a comprehensive range of materials, including clinical guidelines, research papers, treatment protocols, and the latest developments in the field of photopheresis.
This collection is designed to support healthcare providers in their understanding and application of photopheresis in patient care, as well as to assist research scientists in advancing knowledge and best practices.
We aim to provide reliable, evidence-based resources to ensure that professionals across the UK are equipped with the information needed to make informed decisions and contribute to ongoing advancements in the field.
GvHD Hub
Early intervention and use of ECP combinations in cGvHD
Presentation by Florent Malard, Hôpital Saint-Antoine and Sorbonne Université, Paris. This video explored early intervention and ECP-based combinations, including use of ECP first-line, ECP combinations in patients with steroid-refractory and steroid-dependant cGvHD, and recent approvals and findings from clinical trials.
GvHD Hub
Future perspectives of ECP for GvHD treatment
Presentation by Professor Andrew Gennery, Newcastle University and Great North Children’s Hospital, Newcastle upon Tyne, UK, and Chair of the UK Photopheresis Society, about the future directions of extracorporeal photopheresis (ECP) for the treatment of GvHD.
GvHD Hub
The role of ECP in the management of GvHD
Presentation by Professor Hildegard Greinix, Medical University of Graz. This video and article discusses the process of ECP, its direct and indirect effects at a cellular level, and the use of ECP alone or in combination for both chronic and acute GvHD. The impact on quality of life is also considered, with outcomes from multiple research studies.
GvHD Hub
Key considerations for the use of ECP
Presentation by Professor Mohamed Monty, Hospital Saint-Antoine and Sorbonne University, which explores the key considerations for the use of ECP in GvHD. Discussion includes the use of ECP plus steroids in relation to safety and response rates as a first-line treatment option, indications for second-line therapy, as well as example cases.
GvHD Hub
Looking to the future of ECP for the management of GvHD
Professor Daniel Wolff, University Hospital Regensburg, discusses the future use of ECP in patients with GvHD, including methods to explore patient biological profiles to establish predictive biomarkers, and urgent questions for future ECP research.
Therakos Institute
Website with online resources
The Therakos institute aims to advance knowledge and understanding around ECP immunomodulation. This online resources includes on-demand webinars, information on upcoming symposia, speaker meetings and Centres of Excellence.
BMT Infonet
Introduction to chronic GvHD
Video presentation by Dr Corey Cutler, Dana-Farber Cancer Institute, as part of the virtual ‘Celebrating a Second Chance at Life Survivorship’ Symposium, 2020. Contains information on where ECP enters the treatment algorithm. Slides are also available for download.
BMT Infonet
Introduction to GvHD
Video presentation by Dr Andrew Harris, Memorial Sloan Kettering Cancer Centre, as part of the virtual ‘Celebrating a Second Chance at Life Survivorship’ Symposium, 2020. Contains information on ECP usage and long term side effects. Slides are also available for download.
EBMT 2023
The benefit of ECP to reduce the use of corticosteroids in cGvHD
Video presentation by Dr Didier Blaise, MD, PhD, Paoli-Calmettes Institute, commenting on the benefit of ECP to reduce the use of corticosteroids in patients with chronic GvHD, highlighting the importance of using this strategy early on in the treatment of GvHD. This interview took place at the 49th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) held in Paris, France.
EHA 2023
Long-term safety & efficacy of ECP in patients with aGvHD
Video presentation by Dr Eleni Gavriilaki, MD, PhD, Aristotle University of Thessaloniki, commenting on the long-term safety and efficacy of ECP for patients with steroid-dependent or refractory acute GvHD in the second-line setting, and discussing how this treatment strategy might be used in the future. This interview took place at the 28th Congress of the European Hematology Association (EHA) 2023 in Frankfurt, Germany.
ASH 2021
Reviewing the use of ECP in treating CTCL
Video presentation by Dr Francine Foss, MD, Yale University School of Medicine, New Haven, USA, discussing the role of ECP in the treatment of patients with cutaneous T-cell lymphoma (CTCL), especially in Sézary syndrome. A retrospective analysis of patients receiving ECP was performed to assess which patient characteristics affected outcomes, and Prof. Foss emphasizes how the data can refine the use of ECP within the treatment landscape. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.y.
EBMT 2019
Extracorporeal photophoresis for first line GvHD
Video presentation by Dr Florent Malard, MD, PhD, from Hôpital Saint-Antoine, talks about ECP for first line GvHD at the European Society for Blood and Marrow Transplantation (EBMT) 2019 Annual Meeting, held in Frankfurt, Germany.
Advancing health by stimulating research and disseminating knowledge of photopheresis 